2005 President’s Award Presented to Dr. Lisa Minor
News Dec 02, 2005
During the 11th Annual Conference & Exhibition in Geneva, Switzerland, SBS President Al Kolb, presented the 2005 President’s Award to Dr. Lisa Minor for her outstanding efforts in advancing and enhancing the products and services offered by the Society for Biomolecular Sciences.
Each year the President’s Award is given to an SBS member for outstanding contributions to the Society in support of the industry.
An 11-year member of the Society for Biomolecular Sciences, Dr. Minor serves on the Governing Board of the Society and has been involved in initiation of the education initiative of the Society both as a short course instructor as well as a founding member of the education committee.
Currently Principal Scientist at Johnson & Johnson Pharmaceutical Research and Development in Springhouse, Pennsylvania, she joined Johnson & Johnson directly following her postdoctoral studies.
During her 17 years at Johnson & Johnson, Dr. Minor has been a member of therapeutic area teams and a high throughput-screening group.
She has been responsible for developing enzyme and cell culture assays for target identification and high throughput screening, as well as instrumental in developing new technologies for cell-based assays.
Included are assays to measure the translocation of G protein coupled receptors from the membrane to the cytoplasm using cell-based image analysis as well as developing an HTS mRNA detection assay using branched DNA.
At present, Dr. Minor is a member of the Vascular Research Team where she helps direct projects from target identification until compound clinical recommendation.
Dr. Minor received her Ph.D. from Pennsylvania State University where she investigated enzyme regulation in primary cultures of rat hepatocytes.
She received her postdoctoral training at the Medical College of Pennsylvania studying the metabolism of lipid that had accumulated in foam cells.
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE